BR0214822A - Formulações contendo poxvìrus e processo para preparar composições contendo poxvìrus estáveis - Google Patents
Formulações contendo poxvìrus e processo para preparar composições contendo poxvìrus estáveisInfo
- Publication number
- BR0214822A BR0214822A BR0214822-6A BR0214822A BR0214822A BR 0214822 A BR0214822 A BR 0214822A BR 0214822 A BR0214822 A BR 0214822A BR 0214822 A BR0214822 A BR 0214822A
- Authority
- BR
- Brazil
- Prior art keywords
- poxvirus
- preparing stable
- formulations
- preparing
- stable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 238000009472 formulation Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000013011 aqueous formulation Substances 0.000 abstract 2
- 241000700663 Avipoxvirus Species 0.000 abstract 1
- 241000700664 Capripoxvirus Species 0.000 abstract 1
- 241000700639 Parapoxvirus Species 0.000 abstract 1
- 241000700568 Suipoxvirus Species 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 238000012792 lyophilization process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
"FORMULAçõES CONTENDO POXVìRUS E PROCESSO PARA PREPARAR COMPOSIçõES CONTENDO POXVìRUS ESTáVEIS". A presente invenção refere-se a uma formulação, em particular uma formulação aquosa, compreendendo (i) um poxvírus de um dos gêneros ortopoxvírus, avipoxvírus, parapoxvírus, capripoxvírus e suipoxvírus, (ii) um dissacarídeo, (iii) um polímero farmaceuticamente aceitável e opcionalmente (iv) um tampão. A formulação aquosa é particularmente adequada para processos de liofilização resultando em uma composição contendo poxvírus liofilizada estável. A invenção refere-se ainda a um método para preparar uma composição contendo poxvírus liofilizada e ao produto assim obtido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200101831 | 2001-12-10 | ||
PCT/EP2002/013434 WO2003053463A2 (en) | 2001-12-10 | 2002-11-28 | Poxvirus-containing compositions and process for their preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0214822A true BR0214822A (pt) | 2004-12-14 |
Family
ID=8160885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0214822-6A BR0214822A (pt) | 2001-12-10 | 2002-11-28 | Formulações contendo poxvìrus e processo para preparar composições contendo poxvìrus estáveis |
Country Status (22)
Country | Link |
---|---|
US (1) | US7094412B2 (pt) |
EP (1) | EP1418942B1 (pt) |
JP (1) | JP4439263B2 (pt) |
KR (1) | KR20040074067A (pt) |
CN (1) | CN1296096C (pt) |
AT (1) | ATE300954T1 (pt) |
AU (1) | AU2002361962A1 (pt) |
BR (1) | BR0214822A (pt) |
CA (1) | CA2467365C (pt) |
DE (1) | DE60205388T2 (pt) |
DK (1) | DK1418942T3 (pt) |
EA (1) | EA006880B1 (pt) |
ES (1) | ES2247414T3 (pt) |
HK (1) | HK1071295A1 (pt) |
HU (1) | HUP0402179A3 (pt) |
IL (2) | IL161590A0 (pt) |
MX (1) | MXPA04005577A (pt) |
NO (1) | NO20042958L (pt) |
NZ (1) | NZ533302A (pt) |
PL (1) | PL213326B1 (pt) |
UA (1) | UA78738C2 (pt) |
WO (1) | WO2003053463A2 (pt) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
SI1434858T2 (sl) | 2002-09-05 | 2019-05-31 | Bavarian Nordic A/S | Postopek za pomnoževanje poksvirusa v razmerah brez seruma |
CN1207005C (zh) * | 2002-10-31 | 2005-06-22 | 威世药业(如皋)有限公司 | 含生物活性物质的兔皮和其用途 |
WO2006029467A1 (en) * | 2004-09-16 | 2006-03-23 | Btf Pty Ltd | Rapid freeze drying process |
CN101360821A (zh) * | 2005-11-21 | 2009-02-04 | 圣诺菲·帕斯图尔有限公司 | 重组病毒的稳定制剂 |
EP3988651A1 (en) | 2007-05-14 | 2022-04-27 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
WO2008143782A1 (en) * | 2007-05-18 | 2008-11-27 | Medimmune, Llc | Preservation of bioactive materials by freeze dried foam |
US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
EP2486138A1 (en) | 2009-10-08 | 2012-08-15 | Bavarian Nordic A/S | Generation of a broad t-cell response in humans against hiv |
CN103260644A (zh) | 2010-05-21 | 2013-08-21 | 佐蒂斯有限责任公司 | 含有狂犬病毒抗原的副痘病毒载体 |
CN103079593A (zh) | 2010-07-20 | 2013-05-01 | Ah美国42有限责任公司 | 副痘病毒载体 |
DK2596099T3 (da) | 2010-07-20 | 2020-02-24 | Bavarian Nordic As | Fremgangsmåde til høst af ekspressionsprodukter |
DK2788021T3 (en) | 2011-12-09 | 2017-04-10 | Bavarian Nordic As | POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C |
WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
EP2872172B1 (en) | 2012-07-10 | 2018-11-14 | Transgene SA | Mycobacterial antigen vaccine |
TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
DE102013004595A1 (de) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
WO2015104380A1 (en) | 2014-01-09 | 2015-07-16 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
WO2015136056A1 (en) | 2014-03-12 | 2015-09-17 | Bavarian Nordic A/S | Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus |
EP3169341B1 (en) | 2014-07-16 | 2019-06-05 | Transgene SA | Oncolytic virus for expression of immune checkpoint modulators |
RU2704485C2 (ru) | 2014-12-01 | 2019-10-29 | Трансген Са | Стабильные жидкие препараты вируса осповакцины |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
EP3452081A1 (en) | 2016-05-04 | 2019-03-13 | Transgene SA | Combination therapy with cpg tlr9 ligand |
WO2018049261A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus expressing immune checkpoint modulators |
EP3522920A2 (en) | 2016-10-10 | 2019-08-14 | Transgene SA | Immunotherapeutic product and mdsc modulator combination therapy |
WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
WO2018122088A1 (en) | 2016-12-28 | 2018-07-05 | Transgene Sa | Oncolytic viruses and therapeutic molecules |
EP3624845A1 (en) * | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
EP3624851A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
KR20200015759A (ko) | 2017-06-15 | 2020-02-12 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법 |
SG11201912429RA (en) | 2017-06-21 | 2020-01-30 | Transgene Sa | Personalized vaccine |
WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
MX2020009262A (es) | 2018-03-07 | 2021-01-08 | Transgene | Vectores de parapoxvirus. |
WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
CA3111273C (en) | 2018-09-06 | 2024-03-26 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
WO2020090871A1 (ja) | 2018-10-30 | 2020-05-07 | 国立大学法人東京大学 | がん治療のための腫瘍溶解性ウイルス |
WO2020136232A1 (en) | 2018-12-28 | 2020-07-02 | Transgene Sa | Immunosuppressive m2 protein |
CN113453712A (zh) | 2018-12-28 | 2021-09-28 | 特兰斯吉恩股份有限公司 | M2缺陷型痘病毒 |
MX2022011071A (es) | 2020-03-12 | 2022-09-23 | Bavarian Nordic As | Composiciones que mejoran la estabilidad del poxvirus. |
CN116322740A (zh) | 2020-07-13 | 2023-06-23 | 特兰斯吉恩股份有限公司 | 免疫抑制的治疗 |
WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
WO2024003239A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN |
WO2024003238A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | Epstein-barr-virus vaccine |
WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE299213C (pt) | ||||
US4380582A (en) * | 1965-07-09 | 1983-04-19 | The United States Of America As Represented By The Secretary Of The Army | Preparation of dry variola virus |
FR7773M (pt) * | 1968-06-14 | 1970-03-23 | ||
US3577526A (en) * | 1969-06-13 | 1971-05-04 | Merieux Inst | Stabilized smallpox vaccine |
US3915794A (en) * | 1973-02-09 | 1975-10-28 | Rit Rech Ind Therapeut | Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them |
CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
DD299213A7 (de) * | 1988-05-04 | 1992-04-09 | Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De | Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung |
CA2158935A1 (en) * | 1993-10-12 | 1995-04-20 | Chiron Viagene, Inc. | Methods for preserving recombinant viruses |
EP0951555A2 (en) * | 1996-09-24 | 1999-10-27 | Bavarian Nordic Research Institute A/S | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines |
GB9808922D0 (en) * | 1998-04-24 | 1998-06-24 | Cantab Pharmaceuticals Res Ltd | Virus preparations |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
-
2002
- 2002-11-28 HU HU0402179A patent/HUP0402179A3/hu unknown
- 2002-11-28 PL PL369954A patent/PL213326B1/pl unknown
- 2002-11-28 IL IL16159002A patent/IL161590A0/xx unknown
- 2002-11-28 CN CNB028246780A patent/CN1296096C/zh not_active Expired - Fee Related
- 2002-11-28 AT AT02796552T patent/ATE300954T1/de active
- 2002-11-28 DK DK02796552T patent/DK1418942T3/da active
- 2002-11-28 MX MXPA04005577A patent/MXPA04005577A/es active IP Right Grant
- 2002-11-28 KR KR10-2004-7008900A patent/KR20040074067A/ko active Search and Examination
- 2002-11-28 UA UA20040705588A patent/UA78738C2/uk unknown
- 2002-11-28 JP JP2003554220A patent/JP4439263B2/ja not_active Expired - Fee Related
- 2002-11-28 EP EP02796552A patent/EP1418942B1/en not_active Revoked
- 2002-11-28 ES ES02796552T patent/ES2247414T3/es not_active Expired - Lifetime
- 2002-11-28 NZ NZ533302A patent/NZ533302A/en not_active IP Right Cessation
- 2002-11-28 WO PCT/EP2002/013434 patent/WO2003053463A2/en active IP Right Grant
- 2002-11-28 BR BR0214822-6A patent/BR0214822A/pt active Search and Examination
- 2002-11-28 DE DE60205388T patent/DE60205388T2/de not_active Expired - Lifetime
- 2002-11-28 EA EA200400796A patent/EA006880B1/ru not_active IP Right Cessation
- 2002-11-28 US US10/496,858 patent/US7094412B2/en not_active Expired - Lifetime
- 2002-11-28 CA CA2467365A patent/CA2467365C/en not_active Expired - Fee Related
- 2002-11-28 AU AU2002361962A patent/AU2002361962A1/en not_active Abandoned
-
2004
- 2004-04-22 IL IL161590A patent/IL161590A/en not_active IP Right Cessation
- 2004-07-09 NO NO20042958A patent/NO20042958L/no not_active Application Discontinuation
-
2005
- 2005-05-13 HK HK05104050A patent/HK1071295A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2467365A1 (en) | 2003-07-03 |
KR20040074067A (ko) | 2004-08-21 |
IL161590A0 (en) | 2004-09-27 |
WO2003053463A2 (en) | 2003-07-03 |
CA2467365C (en) | 2012-11-20 |
PL213326B1 (pl) | 2013-02-28 |
PL369954A1 (en) | 2005-05-02 |
UA78738C2 (en) | 2007-04-25 |
JP4439263B2 (ja) | 2010-03-24 |
DK1418942T3 (da) | 2005-11-28 |
CN1296096C (zh) | 2007-01-24 |
AU2002361962A1 (en) | 2003-07-09 |
US7094412B2 (en) | 2006-08-22 |
EP1418942A2 (en) | 2004-05-19 |
CN1602205A (zh) | 2005-03-30 |
HK1071295A1 (en) | 2005-07-15 |
HUP0402179A2 (hu) | 2005-01-28 |
DE60205388D1 (de) | 2005-09-08 |
IL161590A (en) | 2009-06-15 |
EP1418942B1 (en) | 2005-08-03 |
US20050019349A1 (en) | 2005-01-27 |
WO2003053463A3 (en) | 2004-03-04 |
HUP0402179A3 (en) | 2012-09-28 |
NZ533302A (en) | 2005-11-25 |
DE60205388T2 (de) | 2006-03-30 |
NO20042958L (no) | 2004-07-09 |
JP2005513109A (ja) | 2005-05-12 |
MXPA04005577A (es) | 2005-04-19 |
EA200400796A1 (ru) | 2004-12-30 |
ATE300954T1 (de) | 2005-08-15 |
ES2247414T3 (es) | 2006-03-01 |
EA006880B1 (ru) | 2006-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0214822A (pt) | Formulações contendo poxvìrus e processo para preparar composições contendo poxvìrus estáveis | |
MXPA01006917A (es) | Composicion topica que comprende n-acetilaldosaminas o acidos n-acetilaminos. | |
GEP20115205B (en) | Controlled release sterile injectable aripiprazole formulation and method | |
MX9200894A (es) | Composiciones terapeuticas para proteger y resucitar las celulas de mamiferos y metodos para preparar y usar las mismas. | |
BR0014512A (pt) | Tratamento tópico para infecções por estreptococos | |
BR0113087A (pt) | Novas composições de minoxidil | |
BR0114393A (pt) | Uso de uma preparação de vìrus envelopado dividido, método para produzir uma formulação de vacina intranasal, uso de uma preparação de vacina de vìrus envolopado dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por vìrus envelopado | |
EP2292263A3 (en) | Compositions and methods for stabilizing biological molecules upon lyophilization | |
MY130477A (en) | Pharmaceutical compositions for the treatmen of mucositis, stomatitis and behcet,s syndrome | |
BR0110420A (pt) | Agonistas muscarìnicos | |
IL159724A0 (en) | A nitrogen oxide generating composition for treatment of nail infections | |
ECSP045496A (es) | "preparaciones acidas de insulina con estabilidad mejorada" | |
BR0214264A (pt) | Composição, processo de preparação da composição e seus usos | |
BR0010249A (pt) | Processo para a preservação de vìrus e micoplasma | |
GEP20053497B (en) | Compositions for Enhanced Acaricidal Activity | |
BRPI0417672A (pt) | processos para produzir composições de vìrus estáveis em armazenamento, composições de vìrus e imunogênicas | |
HUP0303454A2 (hu) | 4-Ciano-trifluor-3-(4-fluor-fenil-szulfonil)-2-hidroxi-2-metil-propiono-m-toluididet és pvp-t tartalmazó szilárd gyógyászati készítmény | |
JP2011520773A (ja) | 爪の外観の改善 | |
AU2001261516A1 (en) | Semi-solid delivery vehicle and pharmaceutical compositions | |
BR0008739A (pt) | Composições de liberação controlada debeta-histina | |
ITRM20010438A1 (it) | Preparato oftalmico a base di n-acetilcisteina per il trattamento della sindrome dell'occhio secco. | |
MXPA03011622A (es) | Uso de glicoproteina para el tratamiento y re-epitelizacion de heridas. | |
BR0104082A (pt) | Processo de tratamento conveniente para a deformação e/ou conformação, e isto de modo permanente, dos materiais queratìnicos e, particulamente, dos cabelos, composição cosmética redutora, e kit para tratamento | |
BR0008336A (pt) | Composição cosmética não enxaguável | |
BRPI0415964A (pt) | uso de um composto, composto, formulação farmacêutica, e, processo para preparar um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: BAVARIAN NORDIC A/S (DK) Free format text: ALTERADA A SEDE DO TITULAR CONFORME REQUERIDA ATRAVES DA PETICAO NO 055511/RJ DE 28/09/2004. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |